168 related articles for article (PubMed ID: 31754710)
1. Pediatric Antiretroviral Therapeutic Drug Monitoring: A Five and a Half Year Experience from a South African Tertiary Hospital.
Engelbrecht AE; Wiesner L; Norman J; Rabie H; Decloedt EH
J Trop Pediatr; 2020 Aug; 66(4):385-394. PubMed ID: 31754710
[TBL] [Abstract][Full Text] [Related]
2. The advantages of therapeutic drug monitoring in patients receiving antiretroviral treatment and experiencing medication-related problems.
Schoenenberger JA; Aragones AM; Cano SM; Puig T; Castello A; Gomez-Arbones X; Porcel JM
Ther Drug Monit; 2013 Feb; 35(1):71-7. PubMed ID: 23188184
[TBL] [Abstract][Full Text] [Related]
3. Adherence to HIV therapeutic drug monitoring guidelines in The Netherlands.
van Luin M; Wit FW; Smit C; Rigter IM; Franssen EJ; Richter C; Kroon F; de Wolf F; Burger DM
Ther Drug Monit; 2011 Feb; 33(1):32-9. PubMed ID: 21192311
[TBL] [Abstract][Full Text] [Related]
4. Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa: A Randomized Clinical Trial.
Coovadia A; Abrams EJ; Strehlau R; Shiau S; Pinillos F; Martens L; Patel F; Hunt G; Tsai WY; Kuhn L
JAMA; 2015 Nov; 314(17):1808-17. PubMed ID: 26529159
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy.
Boulle A; Van Cutsem G; Cohen K; Hilderbrand K; Mathee S; Abrahams M; Goemaere E; Coetzee D; Maartens G
JAMA; 2008 Aug; 300(5):530-9. PubMed ID: 18677025
[TBL] [Abstract][Full Text] [Related]
6. Are lopinavir and efavirenz serum concentrations in HIV-infected children in the therapeutic range in clinical practice?
von Bibra M; Rosenkranz B; Pretorius E; Rabie H; Edson C; Lenker U; Cotton M; Klinker H
Paediatr Int Child Health; 2014 May; 34(2):138-41. PubMed ID: 24225343
[TBL] [Abstract][Full Text] [Related]
7. Impact of Efavirenz-, Ritonavir-Boosted Lopinavir-, and Nevirapine-Based Antiretroviral Regimens on the Pharmacokinetics of Lumefantrine and Safety of Artemether-Lumefantrine in Plasmodium falciparum-Negative HIV-Infected Malawian Adults Stabilized on Antiretroviral Therapy.
Banda CG; Dzinjalamala F; Mukaka M; Mallewa J; Maiden V; Terlouw DJ; Lalloo DG; Khoo SH; Mwapasa V
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30150465
[TBL] [Abstract][Full Text] [Related]
8. A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study.
Reekie J; Reiss P; Ledergerber B; Sedlacek D; Parczewski M; Gatell J; Katlama C; Fätkenheuer G; Lundgren JD; Mocroft A;
HIV Med; 2011 May; 12(5):259-68. PubMed ID: 20812948
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
[TBL] [Abstract][Full Text] [Related]
10. First-line antiretroviral drug discontinuations in children.
Fortuin-de Smidt M; de Waal R; Cohen K; Technau KG; Stinson K; Maartens G; Boulle A; Igumbor EU; Davies MA
PLoS One; 2017; 12(2):e0169762. PubMed ID: 28192529
[TBL] [Abstract][Full Text] [Related]
11. Utility of therapeutic drug monitoring in the management of HIV-infected pregnant women in receipt of lopinavir.
Caswell RJ; Phillips D; Chaponda M; Khoo SH; Taylor GP; Ghanem M; Poulton M; Welch J; Gibbons S; Jackson V; Lambert JS
Int J STD AIDS; 2011 Jan; 22(1):11-4. PubMed ID: 21364060
[TBL] [Abstract][Full Text] [Related]
12. Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults.
Nachega JB; Hislop M; Dowdy DW; Gallant JE; Chaisson RE; Regensberg L; Maartens G
AIDS; 2008 Oct; 22(16):2117-25. PubMed ID: 18832875
[TBL] [Abstract][Full Text] [Related]
13. Plasma concentrations of efavirenz and nevirapine among HIV-infected patients with immunological failure attending a tertiary hospital in North-western Tanzania.
Gunda DW; Kasang C; Kidenya BR; Kabangila R; Mshana SE; Kidola J; Kalluvya SE; Kongola GW; Klinker H
PLoS One; 2013; 8(9):e75118. PubMed ID: 24058655
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs?
Aarnoutse RE; Schapiro JM; Boucher CA; Hekster YA; Burger DM
Drugs; 2003; 63(8):741-53. PubMed ID: 12662123
[TBL] [Abstract][Full Text] [Related]
15. How well does self-reported adherence fare compared to therapeutic drug monitoring in HAART?
Bulgiba A; Mohammed UY; Chik Z; Lee C; Peramalah D
Prev Med; 2013; 57 Suppl():S34-6. PubMed ID: 23313585
[TBL] [Abstract][Full Text] [Related]
16. Is it time to revise antiretrovirals dosing? a pharmacokinetic viewpoint.
Cattaneo D; Baldelli S; Castoldi S; Charbe N; Cozzi V; Fucile S; Clementi E
AIDS; 2014 Oct; 28(16):2477-80. PubMed ID: 25392858
[TBL] [Abstract][Full Text] [Related]
17. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
[TBL] [Abstract][Full Text] [Related]
18. [Efavirenz--comprehensive status of studies].
MMW Fortschr Med; 2005 Apr; 147 Spec No 1():79-81. PubMed ID: 16385886
[No Abstract] [Full Text] [Related]
19. Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals?
Winston A; Pozniak A; Smith N; Fletcher C; Mandalia S; Parmar D; Gibbons S; Back D; Gazzard B; Nelson M
AIDS; 2004 Feb; 18(3):572-4. PubMed ID: 15090815
[TBL] [Abstract][Full Text] [Related]
20. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
